Evidence map›Paper›PMID 36289950›Full record

ArticleAntibiotics (Basel, Switzerland)2022

A Minimal Physiologically Based Pharmacokinetic Model to Characterize CNS Distribution of Metronidazole in Neuro Care ICU Patients.

Alexia Chauzy, Salim Bouchène, Vincent Aranzana-Climent, Jonathan Clarhaut, Christophe Adier, Nicolas Grégoire, William Couet, Claire Dahyot-Fizelier, Sandrine Marchand

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alexia ChauzyUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.ORCID 0000-0001-6443-5888
Salim BouchèneClinical Pharmacology Department, Menarini Stemline, 50131 Florence, Italy.
Vincent Aranzana-ClimentUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.ORCID 0000-0002-1258-8054
Jonathan ClarhautUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
Christophe AdierUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
Nicolas GrégoireUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
William CouetUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
Claire Dahyot-FizelierUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
Sandrine MarchandUFR de Médecine-Pharmacie, Université de Poitiers, Inserm U1070, 86073 Poitiers, France.
Inserm · FRMenarini Group (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding antibiotic concentration-time profiles in the central nervous system (CNS) is crucial to treat severe life-threatening CNS infections, such as nosocomial ventriculitis or meningitis. Yet CNS distribution is likely to be altered in patients with brain damage and infection/inflammation. Our objective was to develop a physiologically based pharmacokinetic (PBPK) model to predict brain concentration-time profiles of antibiotics and to simulate the impact of pathophysiological changes on CNS profiles. A minimal PBPK model consisting of three physiological brain compartments was developed from metronidazole concentrations previously measured in plasma, brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) of eight brain-injured patients. Volumes and blood flows were fixed to their physiological value obtained from the literature. Diffusion clearances characterizing transport across the blood-brain barrier and blood-CSF barrier were estimated from system- and drug-specific parameters and were confirmed from a Caco-2 model. The model described well unbound metronidazole pharmacokinetic profiles in plasma, ECF and CSF. Simulations showed that with metronidazole, an antibiotic with extensive CNS distribution simply governed by passive diffusion, pathophysiological alterations of membrane permeability, brain ECF volume or cerebral blood flow would have no effect on ECF or CSF pharmacokinetic profiles. This work will serve as a starting point for the development of a new PBPK model to describe the CNS distribution of antibiotics with more limited permeability for which pathophysiological conditions are expected to have a greater effect.

Indexed as

blood–brain barrier (BBB)blood-cerebrospinal fluid barrier (BCSFB)central nervous systemmodelling and simulationneuro care ICU patientsphysiologically based pharmacokinetic (PBPK)

Identifiers

PMID36289950
PMCPMC9598284
OpenAlexW4296992696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.